About Us

Quick Company Facts

Front of Innovative Bioanalysis

Management Team

Dr. Dana Yee M.D.

Dr. Dana Yee M.D

Clinical Pathologist and Medical Director

Sam Kabbani, MS, BS, MT(ASCP), CLS

Sam Kabbani, MS, BS, MT(ASCP), CLS

Chief Scientific Officer 

Kevin Noble

Kevin Noble

Laboratory Director and CEO 

Josh Eddy, LEED AP

Director, Engineering Sales 

Teena Rael

Controller

Karen Lam

Lab Manager

Lab Accreditation

In simple terms, being CLIA certified, and CAP accredited ensures your test results are meeting and exceeding industry standards for clinical laboratory testing. The College of American Pathologists (CAP) is such an agency. The CAP releases its own requirements building upon CLIA ’88 regulations.

BSL-3 LEVEL LABORATORY:

Biosafety level 3 (BSL-3) is applicable to laboratories where work is performed with pathogens that may cause serious or potentially lethal disease through inhalation, to the personnel, and may contaminate the environment. It requires that laboratory personnel receive specific training in handling pathogenic and potentially lethal agents and be supervised by scientists competent in handling infectious agents and associated procedures. All work is performed in contained environments using appropriate engineering controls. Access to a BSL-3 laboratory is restricted and always controlled.

BSL-2 LEVEL LABORATORY:

Biosafety level 2 (BSL-2) laboratory involves working with agents that pose moderate hazards to personnel and the environment. Basic laboratory with restricted access and containment during certain processes is required. Use of autoclaves and biological safety cabinets is desired. Use of good laboratory practices, safe waste disposal measures, and aseptic techniques are mandatory. Usually non-respiratory, non-lethal agents are handled in a BSL-2 laboratory. Access to a BSL-2 lab is restricted. Outside personnel are often restricted from entering when work is being conducted.

BEI RECOGNIZED BSL-3:

BEI Resources was established by the National Institute of Allergy and Infectious Diseases (NIAID) to provide reagents, tools and information for studying Category A, B, and C priority pathogens, emerging infectious disease agents, non-pathogenic microbes and other microbiological materials of relevance to the research community.  BEI Resources acquires, authenticates, and produces reagents that scientists need to carry out basic research and develop improved diagnostic tests, vaccines, and therapies. By centralizing these functions within BEI Resources, access to and use of these materials in the scientific community is monitored and quality control of the reagents is assured.

BEI Resources has been managed under contract by American Type Culture Collection (ATCC) since 2003.  A seven-year contract to continue managing BEI Resources was awarded to ATCC in May 2016. The scope of the contract has expanded to a more comprehensive catalog of research materials, including those deposited by other Government-supported research projects, to be made available to the biodefense and emerging infectious disease scientific communities. Fungal, Parasite, Vector and other relevant Materials have been added to the existing Bacterial, Viral and Toxin reagents which cover NIAID Category A, B and C Priority Pathogens and NIAID designated emerging infectious disease agents and organisms.

ATCC RECOGNIZED BSL3:

ATCC is an ISO 9001 certified, ISO 13485 certified, ISO 17025 and ISO 17034 accredited organization. ISO accreditations have allowed ATCC to evolve from a traditional culture collection to Biological Resource Center with an infrastructure that supports the future of life science and biotechnology. BEI Resources has been managed under contract by American Type Culture Collection (ATCC) since 2003.  A seven-year contract to continue managing BEI Resources was awarded to ATCC in May 2016. The scope of the contract has expanded to a more comprehensive catalog of research materials, including those deposited by other Government-supported research projects, to be made available to the biodefense and emerging infectious disease scientific communities. Fungal, Parasite, Vector and other relevant Materials have been added to the existing Bacterial, Viral and Toxin reagents which cover NIAID Category A, B and C Priority Pathogens and NIAID designated emerging infectious disease agents and organisms.